羟氯喹在美国类风湿关节炎退伍军人中的心血管安全性
该研究在8,852例新诊断类风湿关节炎的美国退伍军人中,以倾向评分匹配比较起始羟氯喹(HCQ)与其他非生物DMARD的心血管安全性。随访12个月发现,长QT综合征和心律失常相关住院发生率低,HCQ与心律失常相关住院(HR 1.16,95%CI 0.68-1.95)及全因死亡(HR 1.06,95%CI 0.84-1.34)风险升高无关。
要点
- HCQ组心律失常相关住院HR 1.16(95%CI 0.68-1.95),无显著升高。
- HCQ组全因死亡HR 1.06(95%CI 0.84-1.34),与对照无差异。
- 长QT综合征事件仅3例(0.03%),其中2例在HCQ组。
核心结论
- 在类风湿关节炎患者起始HCQ或其他非生物DMARD后第一年,长QT综合征和心律失常相关住院发生率低,未发现HCQ与不良心血管事件或死亡风险升高相关。
主要发现
- 患者平均年龄64±12岁,女性占14%,非洲裔美国人占28%,两组间87项基线特征均衡。
- 长QT综合征事件共3例(0.03%),其中2例发生于HCQ组。
- 心律失常相关住院共56例(0.63%),HCQ组30例,HCQ相关风险比(HR)为1.16(95%CI 0.68-1.95)。
- 全因死亡HCQ组144例(3.25%)、非HCQ组136例(3.07%),HCQ相关HR为1.06(95%CI 0.84-1.34)。
- 随访前30天内无长QT综合征事件,心律失常相关住院2例(HCQ组0例),死亡13例(HCQ组6例)。
临床怎么用
- 对于新诊断类风湿关节炎患者,起始HCQ治疗时第一年内严重心律失常和死亡风险较低,无需因心血管安全性顾虑而避免使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hydroxychloroquine (HCQ) may prolong the QT interval, a risk factor for torsade de pointes, a potentially fatal ventricular arrhythmia. This study was undertaken to examine the cardiovascular safety of HCQ in patients with rheumatoid arthritis (RA). METHODS: We conducted an active comparator safety study of HCQ in a propensity score-matched cohort of 8,852 US veterans newly diagnosed as having RA between October 1, 2001 and December 31, 2017. Patients were started on HCQ (n = 4,426) or another nonbiologic disease-modifying antirheumatic drug (DMARD; n = 4,426) after RA diagnosis, up to December 31, 2018, and followed up for 12 months after therapy initiation, up to December 31, 2019. RESULTS: Patients had a mean ± SD age of 64 ± 12 years, 14% were women, and 28% were African American. The treatment groups were balanced with regard to 87 baseline characteristics. There were 3 long QT syndrome events (0.03%), 2 of which occurred in patients receiving HCQ. Of the 56 arrhythmia-related hospitalizations (0.63%), 30 occurred in patients in the HCQ group (hazard ratio [HR] associated with HCQ 1.16 [95% confidence interval (95% CI) 0.68-1.95]). All-cause mortality occurred in 144 (3.25%) and 136 (3.07%) of the patients in the HCQ and non-HCQ groups, respectively (HR associated with HCQ 1.06 [95% CI, 0.84-1.34]). During the first 30 days of follow-up, there were no long QT syndrome events, 2 arrhythmia-related hospitalizations (none in the HCQ group), and 13 deaths (6 in the HCQ group). CONCLUSION: Our findings indicate that the incidence of long QT syndrome and arrhythmia-related hospitalization is low in patients with RA during the first year after the initiation of HCQ or another nonbiologic DMARD. We found no evidence that HCQ therapy is associated with a higher risk of adverse cardiovascular events or death.
引用
- Faselis C, Zeng-Treitler Q, Cheng Y, et al. Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis. Arthritis Rheumatol. 2021. PMID: 33973403. doi:10.1002/art.41803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。